Walsh JS, Marshall H, Smith IL, et al. - In this double-blind, placebo-controlled, 6-month trial conducted in the United Kingdom, researchers provided testosterone replacement in young male cancer survivors with borderline low testosterone (7–12 nmol/l) in order to determine the effect of testosterone treatment in this population. Either testosterone (Tostran 2% gel) or placebo was provided for 26 weeks to 136 male survivors of testicular cancer, lymphoma, and leukemia (aged 25–50 years) with morning total serum testosterone 7–12 nmol/l. Following 6 months of testosterone treatment, the young male cancer survivors exhibited a reduction in their fat mass, on average of 1.8 kg and an increase in lean mass of 1.5 kg; however, no differences were observed in the quality-of-life questionnaires between those treated with placebo or testosterone. These findings thus indicate the association of replacement with testosterone with an improvement in body composition among young male cancer survivors with low-normal morning total serum testosterone.